Ajay K. Gade
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ajay K. Gade has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Nathan T. Douthit
Nathan Douthit, MD, is Core Faculty, Department of Graduate Medical Education, Internal Medicine Residency Program, East Alabama Medical Center, Opelika, Alabama, USA, and Co-Chair of Internal Medicine, Department of Clinical Affairs, Edward Via College of Osteopathic Medicine—Auburn Campus, Auburn, Alabama, USA
2 shared publications - Bhavani Nagendra Papudesi
Department of Internal Medicine, Grand Strand Medical Center, Myrtle Beach, USA
1 shared publication - Erin Townsley
Medical Education Internal Medicine, Brookwood Baptist Medical Center, Birmingham, USA
1 shared publication - Eva Olariu
Internal Medicine, Brookwood Baptist Health, Birmingham, USA
1 shared publication - Lauren Pacheco
Internal Medicine, Brookwood Baptist Medical Center, Birmingham, USA
1 shared publication - Sam Joseph
Department of Internal Medicine, Division of Endocrinology, Grand Strand Medical Center, Myrtle Beach, USA
1 shared publication
Latest Publications
- 7 July 2025
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 41 (15) , 4398-4404
Clinical Outcomes in Acute Decompensated Metabolic Dysfunction-associated Steatotic Liver Disease Cirrhosis: The Role of BMI in Mortality, Readmission, and Hospital Stay
Background This study examines the impact of Body Mass Index (BMI) on mortality, readmission rates, and hospital stay lengths in patients with acute decompensated non-alcoholic fatty liver cirrhosis, now termed metabolic dysfunction-associated steatotic liver disease (MASLD). Objective To assess the relationship between BMI and outcomes such as mortality, readmission rates, and hospital and ICU lengths of stay in patients with acute decompensated MASLD. Design Retrospective cohort analysis. Participants Conducted at Grand Strand Medical Center, Myrtle Beach, SC, this study included 43,942 patients, using data from the Hospital Corporation of America Enterprise Data Warehouse from 2017–2022. Main Measures Logistic regression and negative binomial models were used, adjusting for age, gender, race, diabetes, and hyperlipidemia. Key Results A notable “obesity paradox” was observed: underweight patients had over twice the odds of mortality (OR = 2.12, 95% CI: 1.83–2.46; p < 0.0001) compared to healthy-weight patients, suggesting a protective effect of higher BMI. While BMI did not significantly affect overall readmission, patients with Class III obesity had lower readmission odds (OR = 0.86, 95% CI: 0.77–0.96; p = 0.0012). However, Class III obesity was linked to increased hospital (IRR = 1.20, 95% CI: 1.15–1.26; p < 0.0001) and ICU LOS (IRR = 1.12, 95% CI: 1.04–1.20; p < 0.0001). Diabetes (IRR = 1.09, 95% CI: 1.06–1.11) and hyperlipidemia (IRR = 1.34, 95% CI: 1.31–1.38) were also associated with longer LOS (p < 0.0001). Conclusion These findings highlight the complexity of BMI’s role in MASLD outcomes. The observed obesity paradox warrants further investigation to inform care strategies across BMI categories.
- 7 July 2025
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 41 (15) , 4398-4404
Clinical Outcomes in Acute Decompensated Metabolic Dysfunction-associated Steatotic Liver Disease Cirrhosis: The Role of BMI in Mortality, Readmission, and Hospital Stay
Background This study examines the impact of Body Mass Index (BMI) on mortality, readmission rates, and hospital stay lengths in patients with acute decompensated non-alcoholic fatty liver cirrhosis, now termed metabolic dysfunction-associated steatotic liver disease (MASLD). Objective To assess the relationship between BMI and outcomes such as mortality, readmission rates, and hospital and ICU lengths of stay in patients with acute decompensated MASLD. Design Retrospective cohort analysis. Participants Conducted at Grand Strand Medical Center, Myrtle Beach, SC, this study included 43,942 patients, using data from the Hospital Corporation of America Enterprise Data Warehouse from 2017–2022. Main Measures Logistic regression and negative binomial models were used, adjusting for age, gender, race, diabetes, and hyperlipidemia. Key Results A notable “obesity paradox” was observed: underweight patients had over twice the odds of mortality (OR = 2.12, 95% CI: 1.83–2.46; p < 0.0001) compared to healthy-weight patients, suggesting a protective effect of higher BMI. While BMI did not significantly affect overall readmission, patients with Class III obesity had lower readmission odds (OR = 0.86, 95% CI: 0.77–0.96; p = 0.0012). However, Class III obesity was linked to increased hospital (IRR = 1.20, 95% CI: 1.15–1.26; p < 0.0001) and ICU LOS (IRR = 1.12, 95% CI: 1.04–1.20; p < 0.0001). Diabetes (IRR = 1.09, 95% CI: 1.06–1.11) and hyperlipidemia (IRR = 1.34, 95% CI: 1.31–1.38) were also associated with longer LOS (p < 0.0001). Conclusion These findings highlight the complexity of BMI’s role in MASLD outcomes. The observed obesity paradox warrants further investigation to inform care strategies across BMI categories.
- Open Access
- 29 May 2020
- Published by Springer Nature in Cureus
- Vol. 12 (5) , e8351
Medical Management of Crohn's Disease
Crohn's disease (CD) is a chronic inflammatory bowel disease that can affect the entire gastrointestinal tract from the mouth to the anus, sparing the rectum. The goal of medical therapy is to induce remission with medications, followed by the administration of maintenance medications to prevent a relapse of the disease. The concept of induction of remission and maintenance of remission is very important, as there is an overlap of medications used to induce and maintain remission. Physicians first direct treatment to induce a remission that involves relief of symptoms and mucosal healing of the lining of the colon and then provide long-term treatment to maintain the remission. Standard treatment for CD depends on the extent of involvement and disease severity, for example, mild, moderate, severe, and fulminant.
- 29 May 2020
- Published by Springer Nature in Cureus
- Vol. 12 (5) , e8351
Open AccessMedical Management of Crohn's Disease
Crohn's disease (CD) is a chronic inflammatory bowel disease that can affect the entire gastrointestinal tract from the mouth to the anus, sparing the rectum. The goal of medical therapy is to induce remission with medications, followed by the administration of maintenance medications to prevent a relapse of the disease. The concept of induction of remission and maintenance of remission is very important, as there is an overlap of medications used to induce and maintain remission. Physicians first direct treatment to induce a remission that involves relief of symptoms and mucosal healing of the lining of the colon and then provide long-term treatment to maintain the remission. Standard treatment for CD depends on the extent of involvement and disease severity, for example, mild, moderate, severe, and fulminant.
- Open Access
- 5 March 2020
- Published by Springer Nature in Cureus
- Vol. 12 (3) , e7186
Carcinoid Syndrome: A Review
Carcinoid syndrome (CS) is a paraneoplastic syndrome caused by the release of serotonin and other substances from well-differentiated neuroendocrine tumors (NETs). The hallmark symptoms of carcinoid syndrome are flushing and diarrhea; atypical signs and symptoms can include wheezing, abdominal pain, valvular heart disease, telangiectasias, pellagra, and the complications of mesenteric fibrosis, including ureteral obstruction, bowel obstruction, and bowel ischemia. These symptoms are mediated by the release of serotonin (5-HT), histamine, kallikrein, prostaglandins, and tachykinins. The diagnosis of CS requires these symptoms and corresponding elevations in lab tests. Treatment options include surgery and medical management with somatostatin analogs.
- 5 March 2020
- Published by Springer Nature in Cureus
- Vol. 12 (3) , e7186
Open AccessCarcinoid Syndrome: A Review
Carcinoid syndrome (CS) is a paraneoplastic syndrome caused by the release of serotonin and other substances from well-differentiated neuroendocrine tumors (NETs). The hallmark symptoms of carcinoid syndrome are flushing and diarrhea; atypical signs and symptoms can include wheezing, abdominal pain, valvular heart disease, telangiectasias, pellagra, and the complications of mesenteric fibrosis, including ureteral obstruction, bowel obstruction, and bowel ischemia. These symptoms are mediated by the release of serotonin (5-HT), histamine, kallikrein, prostaglandins, and tachykinins. The diagnosis of CS requires these symptoms and corresponding elevations in lab tests. Treatment options include surgery and medical management with somatostatin analogs.
- Open Access
- 25 December 2019
- Published by Springer Nature in Cureus
- Vol. 11 (12) , e6463
A Rare Case of Plummer-Vinson Syndrome
Plummer-Vinson syndrome (PVS) is characterized by a triad of symptoms comprising microcytic hypochromic anemia, esophageal webs, and dysphagia. PVS is commonly found in women of middle age especially in the fourth and fifth decade of life and is rarely reported in males. We report a case of a 39-year-old female patient who had a classic presentation of PVS. PVS is precancerous with high malignant potential; early diagnosis is of utmost importance for better prognosis and surveillance endoscopy is recommended. Iron repletion oftentimes improves the dysphagia; seldom esophageal dilatation is used to provide symptomatic relief.
- 25 December 2019
- Published by Springer Nature in Cureus
- Vol. 11 (12) , e6463
Open AccessA Rare Case of Plummer-Vinson Syndrome
Plummer-Vinson syndrome (PVS) is characterized by a triad of symptoms comprising microcytic hypochromic anemia, esophageal webs, and dysphagia. PVS is commonly found in women of middle age especially in the fourth and fifth decade of life and is rarely reported in males. We report a case of a 39-year-old female patient who had a classic presentation of PVS. PVS is precancerous with high malignant potential; early diagnosis is of utmost importance for better prognosis and surveillance endoscopy is recommended. Iron repletion oftentimes improves the dysphagia; seldom esophageal dilatation is used to provide symptomatic relief.